Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

NCT00948935 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Biliary Cancer
Cholangiocarcinoma

Interventions

DRUG: Gemcitabine, Irinotecan, Panitumumab

Sponsor

Abramson Cancer Center at Penn Medicine